NASDAQ:MNKDMannKind Stock Price, Forecast & News

MannKind's stock was trading at $1.10 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, MNKD shares have increased by 50.9% and is now trading at $1.66.
View which stocks have been most impacted by Coronavirus.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for MannKind in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for MannKind.

MannKind is scheduled to release its next quarterly earnings announcement on Wednesday, August 5th 2020.
View our earnings forecast for MannKind.

MannKind will be holding an earnings conference call on Wednesday, August 5th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

MannKind Co. (NASDAQ:MNKD) issued its quarterly earnings results on Wednesday, May, 6th. The biopharmaceutical company reported ($0.04) earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.06) by $0.02. The biopharmaceutical company earned $16.24 million during the quarter, compared to analysts' expectations of $15.15 million.
View MannKind's earnings history.

5 equities research analysts have issued 12-month price targets for MannKind's stock. Their forecasts range from $2.50 to $4.00. On average, they expect MannKind's stock price to reach $3.00 in the next year. This suggests a possible upside of 80.7% from the stock's current price.
View analysts' price targets for MannKind.

News stories about MNKD stock have been trending somewhat positive recently, InfoTrie reports. The research group ranks the sentiment of news coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. MannKind earned a media sentiment score of 0.8 on InfoTrie's scale. They also assigned media stories about the biopharmaceutical company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an effect on the stock's share price in the next few days.
View the latest news about MannKind.

Some companies that are related to MannKind include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), Seattle Genetics (SGEN), Alexion Pharmaceuticals (ALXN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Immunomedics (IMMU) and Novavax (NVAX).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other MannKind investors own include Bausch Health Companies (BHC), Novavax (NVAX), ACADIA Pharmaceuticals (ACAD), Advanced Micro Devices (AMD), (CHK), Gilead Sciences (GILD), Micron Technology (MU), Geron (GERN), NVIDIA (NVDA) and Intel (INTC).

MannKind trades on the NASDAQ under the ticker symbol "MNKD."

MannKind's stock is owned by a number of retail and institutional investors. Top institutional investors include Emerald Advisers LLC (0.83%), Emerald Mutual Fund Advisers Trust (0.75%), Dupont Capital Management Corp (0.31%), 180 Wealth Advisors LLC (0.22%), Beirne Wealth Consulting Services LLC (0.06%) and SG Americas Securities LLC (0.05%). Company insiders that own MannKind stock include Michael Castagna, Patrick Mccauley, Roxanne S Austin, Steven B Binder and Stuart A Tross.
View institutional ownership trends for MannKind.

MNKD stock was bought by a variety of institutional investors in the last quarter, including Emerald Advisers LLC, Emerald Mutual Fund Advisers Trust, SG Americas Securities LLC, 180 Wealth Advisors LLC, Beirne Wealth Consulting Services LLC, ProShare Advisors LLC, and Dupont Capital Management Corp. Company insiders that have bought MannKind stock in the last two years include Michael Castagna, Patrick Mccauley, Roxanne S Austin, Steven B Binder, and Stuart A Tross.
View insider buying and selling activity for MannKind.

Shares of MNKD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of MNKD stock can currently be purchased for approximately $1.66.

MannKind has a market capitalization of $353.81 million and generates $63.04 million in revenue each year. The biopharmaceutical company earns $-51,900,000.00 in net income (profit) each year or ($0.27) on an earnings per share basis. MannKind employs 225 workers across the globe.

The official website for MannKind is www.mannkindcorp.com.

MannKind's mailing address is 30930 RUSSELL RANCH ROAD SUITE 300, WESTLAKE VILLAGE CA, 91362. The biopharmaceutical company can be reached via phone at 818-661-5000 or via email at [email protected]